| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Ouabagenin, an aglycone of cardiotonic steroidal glycoside Ouabain, has been thought to be a non-bioactive precursor for biosynthesis of ouabain. In our study, ouabagnin was revealed to show ligandable activity for liver X receptor (LXR). In addition, ouabagenin was disclosed to down-regulate the expression level of epithelial sodium channel (ENaC) on the cells of collecting duct whereas not to lead hepatic steatosis which was normally induced by typical LXR ligands. Thus, ouabagnin is a one of the promising medical seeds as antihypertensive diuretic and useful chemical tool for exploration for LXR. Further investigation is necessary for analysis of the relationship between ouabagenin and ouabain as endogenous factors.
|
